CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Has Consensus Price Target of $11.90 According to Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have earned a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $11.90.

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. decreased their target price on shares of CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating on the stock in a report on Thursday, August 13th. Wall Street Zen lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. Weiss Ratings reissued a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Friday, September 11th. Zacks Research cut CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Guggenheim cut their price objective on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 10th.

Institutional Trading of CytomX Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC bought a new position in CytomX Therapeutics in the second quarter valued at about $47,000. Nierenberg Investment Management Company LLC purchased a new position in CytomX Therapeutics in the second quarter worth about $47,081. Lido Advisors LLC bought a new stake in shares of CytomX Therapeutics during the 1st quarter valued at about $49,000. TRB Wealth Management LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at about $50,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of CytomX Therapeutics during the 1st quarter valued at about $52,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

NASDAQ:CTMX opened at $2.36 on Thursday. CytomX Therapeutics has a one year low of $2.16 and a one year high of $8.21. The company has a market cap of $514.24 million, a PE ratio of -4.72 and a beta of 2.21. The firm’s 50 day simple moving average is $2.87 and its 200 day simple moving average is $3.89.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $1.42 million for the quarter, compared to the consensus estimate of $12.39 million. CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. Equities research analysts expect that CytomX Therapeutics will post -0.40 EPS for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.